2 studies prove Revlimid's efficacy as maintenance therapy

05/20/2010 | Reuters

The risk of multiple myeloma progression was reduced by more than 50% in stem cell transplant patients who received Celgene's Revlimid as maintenance therapy, two studies showed. One of the clinical trials also noted an 88% survival rate for Revlimid patients after three years, compared with 80% in the group that took a placebo.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations